Dihexa for Baby Brain, Pregnancy & Postpartum Brain Fog: The Maternal Brain, the Estrogen-BDNF Crash, Neurosteroids & the 2026 UK Review

"Baby brain", "mum brain" and "momnesia" were dismissed for years as folklore — and then the neuroscience caught up. The Davies 2018 Medical Journal of Australia meta-analysis of 20 studies (709 pregnant and 521 non-pregnant women) found general cognition, memory and executive function measurably poorer in pregnancy, especially in the third trimester. Hoekzema and colleagues (2017, Nature Neuroscience) then showed pregnancy physically remodels the brain, reducing gray matter in social-cognition regions so consistently that the change persisted for at least two years — and in 2024 Pritschet, Jacobs and Chrastil mapped it week by week across a single pregnancy with 26 brain scans. Postpartum, the picture sharpens: estradiol and progesterone crash within days of birth, dragging down the estrogen-BDNF signalling that supports memory and mood, while the neurosteroid allopregnanolone collapse drives the postpartum-depression biology now targeted by zuranolone. Because that endpoint — reduced hippocampal BDNF-TrkB plasticity — is the same one Dihexa, an HGF/c-Met synaptogenic peptide, also reaches, the question gets asked. This 2026 UK review answers it carefully: the maternal-brain science, the treatable drivers, the BDNF-HGF-c-Met chain — and the single most important conclusion, which is that pregnancy and breastfeeding are absolute contraindications for an unlicensed research chemical that acts on a pathway essential to building a placenta and a baby.

Baby Brain in the UK in 2026: A Near-Universal Experience

"Baby brain" — also called "mum brain", "pregnancy brain" or, in the US, "mommy brain" and "momnesia" — describes the forgetfulness, slowed thinking, distractibility and word-finding difficulty that a large majority of women report during pregnancy and the early months after birth. For a long time it was treated as a cultural meme rather than a clinical phenomenon, and women describing it were sometimes met with a shrug. That has changed decisively over the past decade as imaging and meta-analytic evidence has accumulated.

The scale is enormous. The Office for National Statistics recorded 567,708 live births in England in 2024, with a total fertility rate of 1.41 — the lowest on record for the third year running, but still close to 600,000 pregnancies reaching birth in England each year. Surveys consistently find that the majority of pregnant and newly postpartum women notice some degree of cognitive change, which makes this one of the most widely experienced — and most heavily searched — cognitive complaints in the country. It is also one of the most reassuring, because for most women it is transient and self-limiting.

The key 2026 framing, and the thread that runs through this entire review, is that baby brain sits at the intersection of three things that are not diseases to be drugged: an adaptive remodelling of the maternal brain, a steep but normal hormonal transition, and the ordinary physiological toll of late pregnancy and newborn care. Where it tips into something that does need treatment — postnatal depression, postpartum anxiety, thyroid disease, anaemia — the answer is assessment and established care, not experimentation. This is the same logic applied to menopause brain fog and PCOS brain fog elsewhere on this site: when treatable causes dominate, an unlicensed peptide is essentially last on the list — and in pregnancy it is off the list entirely.

Is Baby Brain Real? What the Cognition Data Actually Show

The strongest single piece of evidence is the Davies and colleagues 2018 meta-analysis in the Medical Journal of Australia. Pooling 20 studies that compared 709 pregnant women with 521 non-pregnant controls, the authors found that overall cognitive functioning was significantly poorer in pregnancy (standardised mean difference around 0.5), with general cognition, memory and executive function all affected, and the deficits most pronounced in the third trimester. Importantly, the differences began to appear in the first trimester, which argues against the idea that they are simply the product of late-pregnancy discomfort or sleep loss alone.

Two caveats keep this honest. First, the effect sizes are modest: pregnant women as a group perform slightly worse on demanding laboratory tasks, but they remain well within the normal range and the changes are not disabling for most. The gap between the dramatic subjective experience and the modest measured deficit is itself interesting — expectation, fatigue and the sheer cognitive load of pregnancy and new parenthood amplify how impaired women feel relative to how they test. Second, much of the laboratory deficit concentrates on the most effortful memory and executive tasks, while everyday and emotionally salient memory is often preserved or even enhanced. The picture is of reallocation, not collapse.

This mirrors a recurring theme across the cognitive conditions reviewed on this site: subjective brain fog is real and worth taking seriously, but its intensity is shaped by sleep, stress and expectation as much as by any single lesion — a pattern also seen in Long COVID brain fog and anxiety and chronic stress.

The Maternal Brain: How Pregnancy Physically Remodels Grey Matter

The reason baby brain stopped being dismissible is that researchers can now see the maternal brain change. The landmark study is Hoekzema and colleagues (2017, Nature Neuroscience), which scanned women before and after their first pregnancy and found consistent reductions in gray matter volume in regions involved in social cognition — the "theory of mind" network that helps a person infer the mental states of others. The changes were so reliable that an algorithm could classify, from the brain scan alone, which women had recently been pregnant. They persisted for at least two years after birth, and the degree of change predicted measures of maternal attachment, while hippocampal volume partially recovered over the same period in parallel with cognitive recovery.

The interpretation matters enormously. Hoekzema's team, and the field since, frame this gray-matter reduction not as damage or atrophy but as adaptive specialisation — conceptually similar to the synaptic pruning that refines the adolescent brain, in which weaker, redundant connections are removed to produce a more efficient, purpose-tuned network. On this reading the maternal brain is being optimised for caregiving and infant-cue sensitivity, at a temporary cost to some general cognitive performance. "Less volume" here plausibly means "more finely tuned", not "worse".

In September 2024, Pritschet, Jacobs and Chrastil published a precision-imaging study in Nature Neuroscience that took this from before-and-after snapshots to a continuous film. By scanning a single first-time mother 26 times — from three weeks before conception through to two years postpartum — they showed gray matter volume and cortical thickness declining across most of the cerebral cortex and major brain networks as pregnancy progressed, alongside a transient mid-gestation rise in white-matter microstructural integrity and increases in cerebrospinal-fluid spaces. Some of these measures partially rebounded after birth; others did not. The summary from the US National Institutes of Health captured the consensus: this looks like dynamic, hormonally driven "fine-tuning" of brain circuitry. The work has since been extended by the Maternal Brain Project and by 2025–2026 cohorts examining changes across second pregnancies, building a far richer map of a life stage that neuroscience had almost entirely ignored.

The Postpartum Hormone Crash: Estrogen, BDNF and Neurosteroids

If pregnancy is a slow remodelling, the postpartum period opens with an abrupt neuroendocrine cliff. During pregnancy, placental output drives estradiol and progesterone to levels many times higher than at any other point in life. With delivery of the placenta, both fall back toward baseline within days — one of the steepest hormonal transitions the human body undergoes. That crash is the hinge on which much of postpartum cognition and mood turns.

The estrogen-BDNF axis

Estradiol is not just a reproductive hormone; in the forebrain and hippocampus it up-regulates brain-derived neurotrophic factor (BDNF), the growth factor that, through its TrkB receptor, drives dendritic spine maturation, long-term potentiation and memory consolidation. When estradiol is high in pregnancy, this support is amplified; when it collapses postpartum, BDNF-dependent plasticity signalling transiently weakens, and serum BDNF itself tends to be lower around late pregnancy and the early postpartum window. This is the same estrogen-BDNF coupling that explains cognitive symptoms in menopause and perimenopause — the postpartum period is, in effect, a sudden, temporary estrogen-withdrawal state.

Allopregnanolone and the GABA-A story

Progesterone's neuroactive metabolite, allopregnanolone, is a potent positive modulator of the GABA-A receptor — the brain's main inhibitory, calming system. It rises through pregnancy and falls sharply after birth. The leading neurobiological model of postnatal depression holds that some women's GABA-A systems fail to re-adapt smoothly to this withdrawal, producing the anxiety, low mood and cognitive symptoms of postpartum depression. This is not a fringe idea: it is the mechanism behind two licensed treatments.

Brexanolone and zuranolone: treating the actual neurochemistry

Brexanolone (Zulresso), approved in 2019, is a synthetic allopregnanolone given as an intravenous infusion in hospital. Zuranolone (Zurzuvae), approved by the FDA in August 2023, is the first oral treatment specifically for postpartum depression — a 14-day course of a neuroactive-steroid GABA-A modulator that can improve symptoms within days. These drugs are worth dwelling on precisely because they are the responsible counterpoint to a research chemical: they target the documented postpartum neurochemistry, went through controlled trials, and are prescribed and monitored. When people ask whether Dihexa "does the same thing", the honest answer is no — it acts on a different pathway, has never been trialled here, and is contraindicated in exactly the population these drugs are designed for.

The Treatable Drivers: Sleep, Thyroid, Iron and Mood

Before any conversation about novel compounds, the postpartum cognitive picture is dominated by a handful of common, correctable contributors — and addressing them is where the real gains are.

Sleep fragmentation

Newborn care shatters sleep architecture, and chronic sleep deprivation is itself one of the most reliable causes of impaired attention, working memory and processing speed in any population. A large share of what feels like "postpartum brain fog" is the cognitive signature of months of broken sleep. It is also, partially, addressable — sharing night feeds, protecting daytime rest, and recognising that the fog often lifts substantially once the infant's sleep consolidates. The mechanistic overlap with sleep and memory consolidation is direct: the same nocturnal processes that consolidate memory are the ones a newborn disrupts.

Postpartum thyroiditis

Around 5–7% of women develop postpartum thyroiditis in the year after birth — a transient autoimmune thyroid disturbance that can cause fatigue, low mood and cognitive slowing, and is easily missed because its symptoms are attributed to new motherhood. A simple thyroid panel identifies it, and it overlaps directly with the Hashimoto's and hypothyroid brain fog picture covered elsewhere on this site. Checking thyroid function in persistent postpartum brain fog is basic, high-yield medicine.

Iron deficiency and anaemia

Blood loss at delivery, on top of the iron demands of pregnancy, makes iron deficiency and iron-deficiency anaemia common postpartum. Iron deficiency — even without frank anaemia — impairs attention and processing speed, and B12 and folate status matter too. These are correctable with testing and replacement, and like the thyroid check, they belong firmly ahead of any experimental option.

Postnatal depression and anxiety

The most important overlap of all: postpartum cognitive symptoms frequently travel with postnatal depression or postpartum anxiety. In England, the Royal College of Psychiatrists estimated in July 2025 that between 56,000 and 85,000 mothers (10–15%) experienced postnatal depression in 2024, and perinatal mental illness affects up to one in five new and expectant mothers. Tragically, maternal mental illness remains a leading cause of maternal death between six weeks and a year after birth. This is the clearest possible reason not to reach for a peptide that could blunt a symptom while leaving a serious, treatable condition unaddressed — and it is why the depression and mood review on this site reaches the same conclusion.

The BDNF-HGF-c-Met Chain: Where Dihexa Enters the Story

Having mapped the biology, we can state precisely why the Dihexa question even arises. Postpartum cognitive vulnerability converges on a familiar endpoint: reduced hippocampal BDNF-TrkB signalling and impaired synaptic plasticity, downstream of the estrogen crash, sleep loss and inflammation. That endpoint is the one Dihexa is designed to push in the opposite direction.

Dihexa (PNB-0408) is an orally and topically active angiotensin IV analogue that acts as a positive modulator of the hepatocyte growth factor (HGF) and its receptor c-Met. Through that pathway it promotes dendritic spine formation and synaptogenesis, and in preclinical work it has been described as extraordinarily potent at facilitating new synapse formation. The HGF/c-Met route is partly independent of, but functionally parallel to, the BDNF-TrkB system — which is exactly why a compound that boosts synaptogenesis gets floated for any condition where BDNF-dependent plasticity is flagging, from mild cognitive impairment to, in this case, the postpartum brain.

But the chain has a critical break in it. Mechanistic overlap is a hypothesis-generator, not evidence of benefit, and the postpartum endpoint is reached by a route — hormone withdrawal plus sleep loss — that resolves on its own as hormones re-stabilise and sleep returns. Pushing synaptogenesis pharmacologically into a brain that is actively, adaptively remodelling and is expected to recover is a very different proposition from supporting a degenerating one. And as the next section makes clear, in this particular population the mechanism is not merely unproven — it is hazardous.

Why HGF/c-Met Makes Dihexa Contraindicated in Pregnancy and Breastfeeding

This is the section that matters most, and it is unusually clear-cut. The very mechanism that makes Dihexa interesting for cognition makes it dangerous around reproduction.

HGF and its receptor c-Met are not brain-specific. They are among the most important signalling systems in building a pregnancy. HGF/c-Met signalling drives trophoblast proliferation and invasion — the process by which the placenta embeds in and remodels the uterine wall — and is central to placental development and to fetal organogenesis, including the formation of the liver, skeletal muscle and the nervous system. In animal models, complete genetic loss of c-Met is embryonic-lethal: embryos cannot develop a normal placenta or fetal liver and muscle without it. A pathway this fundamental to placentation and fetal growth is precisely the pathway you do not perturb pharmacologically during pregnancy.

Layer onto that the simple regulatory reality: Dihexa is an unlicensed research chemical with no reproductive or developmental toxicology data in humans, no pharmacokinetic data on placental transfer, and no data on excretion into breast milk. For a breastfeeding mother, an uncharacterised, growth-factor-modulating peptide of unknown milk transfer is being introduced to a rapidly developing infant whose own tissues depend on tightly regulated HGF/c-Met signalling. There is no version of a risk-benefit calculation that favours this. The benefit is hypothetical and unproven; the potential harm is to a placenta or a baby and is essentially unquantifiable.

The Fosgonimeton Parallel: The Mechanism Has Already Disappointed

Even setting the reproductive contraindication aside, the HGF/c-Met cognitive thesis has a sobering clinical track record. Fosgonimeton (ATH-1017), developed by Athira Pharma, is the most clinically advanced molecule built on the same HGF/MET positive-modulation idea as Dihexa. It reached Phase 3 in Alzheimer's disease — and in 2024 its pivotal LIFT-AD trial missed its primary cognitive endpoint.

The lesson is not that the mechanism is worthless, but that translating "promotes synaptogenesis in a dish and in rodents" into "improves human cognition in a real disease" has so far failed at the most rigorous stage of testing. If a purpose-built, professionally developed, properly dosed HGF/MET modulator could not beat placebo on cognition in a controlled Alzheimer's trial, the case for self-administering an unlicensed analogue for a transient, self-resolving, hormonally driven phenomenon like baby brain — in the one population where it is also developmentally hazardous — collapses entirely.

What Actually Helps — The Evidence-Based Approach

The encouraging reality is that pregnancy and postpartum cognitive change is one of the more recoverable forms of brain fog, and the effective steps are safe, cheap and well-established.

Protect sleep wherever it is humanly possible — sharing or alternating night feeds, accepting help, and resting in the day are not indulgences but cognitive medicine. Get the basics checked: a thyroid panel and iron studies (ferritin, plus B12 and folate) catch the most common treatable drivers. Keep moving within whatever your midwife or GP advises, because physical activity is one of the few interventions that reliably and safely raises BDNF. Eat to support recovery, stay hydrated, and lower the cognitive load where you can — lists, reminders and lowered expectations are legitimate tools, not failures.

Above all, treat persistent low mood, anxiety, tearfulness or intrusive thoughts as signals to seek help rather than symptoms to push through. In the UK, your GP, midwife and health visitor are the front door; the NHS now runs specialist perinatal mental health services in every region, and charities such as the PANDAS Foundation offer peer support. Where postnatal depression is diagnosed, there are real, evidence-based treatments — talking therapies, antidepressants where appropriate, and now neurosteroid options — that target the actual problem. And for the cognitive change itself, the most reliable treatment is time: the maternal brain re-stabilises over the months to roughly two years after birth, with the hippocampal recovery Hoekzema documented.

Who Should Absolutely Not Consider Dihexa Here

To be completely direct, because this is a population where vague hedging would be a disservice: anyone who is pregnant, trying to conceive, or breastfeeding should not use Dihexa for baby brain, postpartum brain fog, postnatal depression or any other reason. The reproductive and developmental risk described above is not theoretical hand-waving; it follows from the core biology of the pathway Dihexa acts on, combined with a total absence of safety data.

The general contraindications that apply to everyone apply here too, and some are sharpened by context. Because c-Met signalling is implicated in tumour growth and invasion, anyone with a personal or family history of c-Met-relevant cancers should avoid Dihexa entirely. And as a matter of basic harm-avoidance, no one should substitute an unregulated compound for the assessment of a postpartum mood disorder, thyroid problem or anaemia. If you take only one thing from this review, let it be this: in the perinatal window, the right list of things to try does not include Dihexa at all.

The Bottom Line

Baby brain, pregnancy brain fog and postpartum "mum brain" are real, common and now well-characterised. The cognition data (Davies 2018) show modest but genuine deficits; the imaging data (Hoekzema 2017, Pritschet 2024) show a maternal brain that physically remodels in an adaptive, largely reversible way; and the postpartum experience is sharpened by a steep estrogen and neurosteroid withdrawal that drags BDNF-dependent plasticity down with it and, in some women, tips into postnatal depression. Almost everything that helps is safe and established: sleep, nutritional correction, thyroid and iron checks, activity, time, and proper mental-health care where mood is affected.

Dihexa, by contrast, is mechanistically coherent on paper and clinically unproven in practice — its closest developed relative failed Phase 3 — and in this specific population it is not just unproven but contraindicated, because it acts on a pathway essential to building a placenta and a baby and has no developmental safety data whatsoever. The maternal brain does not need a synaptogenic research chemical pushed into the middle of a remodelling it is doing on purpose. It needs sleep, support, the right checks, and time — and, where the line into illness is crossed, the real treatments that already exist.

Frequently Asked Questions

Related Reading on Dihexa.co.uk

• Dihexa for Menopause & Perimenopause Brain Fog (2026) — the same estrogen-BDNF-synaptic axis, at the other end of reproductive life.
• Dihexa for PCOS (PMOS) Brain Fog (2026) — another hormonally driven cognitive picture in women's health.
• Dihexa for Endometriosis Brain Fog (2026) — chronic-condition cognitive dysfunction and the directionality problem.
• Dihexa for Hashimoto's & Hypothyroid Brain Fog (2026) — postpartum thyroiditis sits in this family of treatable drivers.
• Dihexa for Depression & Mood (2026) — the synaptogenic-neuroplasticity hypothesis and why mood needs proper care.
• Dihexa for Anxiety & Chronic Stress (2026) — how stress and expectation shape subjective cognition.
• Dihexa, Sleep & Memory Consolidation (2026) — the sleep mechanism a newborn disrupts.
• Dihexa for MCI & Brain Aging (2026) — the BDNF-TrkB endpoint postpartum brain fog shares.
• Dihexa for Long COVID Brain Fog (2026) — another real-but-multifactorial brain-fog comparator.
• Dihexa vs BDNF: What "10 Million Times More Potent" Actually Means — an in-depth look at the BDNF mechanism claim.
• Mechanism of Action — HGF/c-Met, PI-3K/AKT, dendritic spines, cerebrovascular angiogenesis.
• Side Effects & Risks — the general safety picture, including the c-Met oncology caution.
• UK Legal Status — where Dihexa sits in UK law and MHRA advertising rules.
• Fosgonimeton & Athira — the cautionary Phase 3 story for this mechanism.

External Authoritative Sources Cited

• Davies SJ, Lum JAG, Skouteris H, Byrne LK, Hayden MJ (Medical Journal of Australia, 2018). Cognitive impairment during pregnancy: a meta-analysis.
• Hoekzema E et al. (Nature Neuroscience, 2017). Pregnancy leads to long-lasting changes in human brain structure.
• Pritschet L, Taylor CM, Cossio D, et al. (Nature Neuroscience, 2024). Neuroanatomical changes observed over the course of a human pregnancy.
• US National Institutes of Health — Brain changes observed during pregnancy (research summary, 2024).
• University of California, Santa Barbara — New study reveals changes in the brain throughout pregnancy (2024).
• The Maternal Brain Project — Ann S. Bowers Women's Brain Health Initiative.
• US FDA — FDA approves first oral treatment for postpartum depression (zuranolone / Zurzuvae, August 2023).
• Schiller CE, Meltzer-Brody S, Rubinow DR (CNS Spectrums, 2015). The role of reproductive hormones in postpartum depression.
• Brain-derived neurotrophic factor (BDNF) in perinatal depression: side show or pivotal factor? (2023).
• Office for National Statistics — Births in England and Wales: 2024.
• Royal College of Psychiatrists — Postnatal depression harming up to 85,000 new mums in England (July 2025).
• NHS England — Perinatal mental health services.
• PANDAS Foundation — UK perinatal mental health support charity.
• NHS — Postnatal depression overview.
• HGF and MET in brain development and neurological disorders (Frontiers in Cell and Developmental Biology, 2021).
• Benoist CC et al. (JPET, 2014). Dihexa procognitive effects via HGF/Met.